Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | 阶段
Phase 1, Phase 2
|
Date Added 2023-02-06 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-04-03 |
地点
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NT-I7, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2019-08-01 |
地点
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States 比利时 加拿大 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT05213195 |
Title难治性转移性结直肠癌患者的 NKG2D CAR-NK 细胞疗法 | 阶段
第 1 阶段
|
Date Added 2022-01-28 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
NKG2D CAR-NK |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | 阶段
第二阶段
|
Date Added 2020-10-05 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03104439 |
TitleNivolumab 和 Ipilimumab 以及放疗治疗 MSS 和 MSI 高的结直肠癌和胰腺癌 | 阶段
第二阶段
|
Date Added 2017-04-07 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03983993 |
TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-06-12 |
地点
Georgia, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Niraparib, panitumumab, Vectibix, Zejula |
标签
MSS/ MMRp
|
| NCT ID NCT04940546 |
TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | 阶段
Phase 1, Phase 2
|
Date Added 2021-06-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, oxaliplatin, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | 阶段
第 1 阶段
|
Date Added 2023-04-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cyclophosphamide, Fludarabine, Interleukin-2 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | 阶段
第 1 阶段
|
Date Added 2023-03-24 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
